EMA Authorised: Abiraterone Mylan (abiraterone acetate) — Mylan Pharmaceuticals Limited

View source ↗

Summary

The EMA authorised Abiraterone Mylan (abiraterone acetate) for prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone Mylan (abiraterone acetate)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Mylan Pharmaceuticals Limited. Decision date: 19/01/2026